medwireNews: ASCO has issued evidence-based recommendations to guide the management of stage III non-small-cell lung cancer (NSCLC).
“This guideline reviews the published evidence addressing diagnosis and management of stage III NSCLC and provides evidence-based guidance on the common clinical dilemmas that clinicians may have while evaluating a patient with suspected or known stage III NSCLC,” write the authors in the Journal of Clinical Oncology.
The recommendations cover the following key topics: evaluation and staging; surgery; neoadjuvant and adjuvant therapy; and management of unresectable disease.
The resource was developed by a multidisciplinary panel comprising medical, radiation, pulmonary, and community oncologists as well as experts in thoracic surgery, research methodology, and advocacy. They drew upon 127 studies published between January 1990 and August 2021 – including 23 systematic reviews and meta-analyses, two pooled analyses, 91 randomized controlled trials (six with multiple publications), and four phase 2 trials – to form the evidence base for the document.
“The ASCO Expert Panel and guidelines staff will work with cochairs to keep abreast of any substantive updates to the guideline,” say the authors.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group